Evidence map›Paper›PMID 38488881›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

Stereotactic body radiotherapy for distant metastases to the head and neck.

Adam Mutsaers, Ahmed Abugharib, Ian Poon, Joshua Loblaw, Andrew Bayley, Liying Zhang, Lee Chin, Madette Galapin, Darby Erler, Arjun Sahgal and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Adam MutsaersDepartment of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Ahmed AbugharibDepartment of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Ian PoonDepartment of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Joshua LoblawDepartment of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Andrew BayleyDepartment of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Liying ZhangDepartment of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Lee ChinDepartment of Medical Physics, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Madette GalapinDepartment of Radiation Therapy, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Darby ErlerDepartment of Radiation Therapy, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Arjun SahgalDepartment of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Kevin HigginsDepartment of Otolaryngology - Head and Neck Surgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Danny EnepekidesDepartment of Otolaryngology - Head and Neck Surgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Antoine EskanderDepartment of Otolaryngology - Head and Neck Surgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Irene KaramDepartment of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. Irene.Karam@sunnybrook.ca.
Health Sciences Centre · CASunnybrook Health Science Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo report clinical outcomes for patients with metastatic disease to the head and neck (HN) treated with stereotactic body radiation therapy (SBRT).

methodsA retrospective review of patients treated with SBRT to HN sites from 2012 to 2020 was conducted. Treatment indications included the following: oligometastases, oligoprogression, and control a dominant area of progression (DAP). Kaplan-Meier method was used to estimate local control (LC), regional control (RC), overall survival (OS), and progression-free survival (PFS). Univariable (UVA) and multivariable analyses (MVA) were performed. Grade 3-4 acute and late toxicities were reported by the Common Terminology Criteria for Adverse Events v5.0.

resultsFifty-six patients (58 lesions) were analysed with a median follow-up of 16 months. Primary sites included lung (25.0%), kidney (19.6%), breast (19.6%) and other (35.8%). SBRT indications were as follows: oligometastases (42.9%), oligoprogression (19.6%) and local control of a dominant area of progression (37.5%). Most patients received SBRT to a single neck node (n = 47, 81.0%). Median SBRT dose was 40 Gy (range 25-50 Gy) in five fractions, with a median biologically effective dose (BED

conclusionThe use of SBRT for metastatic disease to the HN provided excellent LC rates with low rates of regional failure and an acceptable toxicity profile, highlighting its utility in these patients. Patients with oligometastatic disease had better OS and PFS than others.

Indexed as

Lung NeoplasmsRadiosurgeryHumansLungNeckProgression-Free SurvivalRetrospective StudiesHead and neckMetastasesStereotactic body radiotherapy

Identifiers

PMID38488881
OpenAlexW4392863540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.